Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

6.24USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$6.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,144
52-wk High
$11.11
52-wk Low
$4.03

Select another date:

Thu, Jan 4 2018

BRIEF-Foamix Announces Positive Results From Late Stage Acne Treatment Study

* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:

BRIEF-Foamix Names David Domzalski As A Member Of Company Board

* FOAMIX NAMES MR. DAVID DOMZALSKI AS A MEMBER OF THE BOARD OF FOAMIX PHARMACEUTICALS

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

BRIEF-Foamix Q2 loss per share $0.44

* Foamix reports second quarter 2017 financial results and provides business update

BRIEF-Foamix says expects to report top-line results from study FX2017-22 by mid-2018​

* Foamix announces dosing of first patient in third phase 3 acne study for minocycline foam fmx101

Select another date: